Search

Your search keyword '"Derache, Nathalie"' showing total 156 results

Search Constraints

Start Over You searched for: Author "Derache, Nathalie" Remove constraint Author: "Derache, Nathalie"
156 results on '"Derache, Nathalie"'

Search Results

1. Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

2. Neurologic manifestations associated with COVID-19: a multicentre registry

4. Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study

5. Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.

6. Anti-Argonaute antibodies as a potential biomarker in NMOSD

10. Multi-center, Randomized, Double-blinded Assessment of TERIFLUNOMIDE (Aubagio®) in Extending the Time to the First Attack in Radiologically Isolated Syndrome: Baseline Characteristics of the TERIS Study. (P5-4.011)

11. Prospective Characterization of Brain T2 Lesions Suggestive of Demyelination in Asymptomatic Patients diagnosed as Radiologically Isolated Syndrome (P14-4.011)

13. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica

14. Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification

15. Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients

16. Heterozygous HTRA1 nonsense or frameshift mutations are pathogenic

19. BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS

20. Neurologic manifestations associated with COVID-19: a multicentre registry

21. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.

25. BEST-MS: A Standardized and Prospective Study Comparing the Efficacy of Natalizumab versus Fingolimod in Active Relapsing Multiple Sclerosis. (769)

26. Biallelic MYORG mutation carriers exhibit primary brain calcification with a distinct phenotype

27. MSJ849511_supplemental_figure – Supplemental material for Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study

28. BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.

29. Inflammatory-like presentation of CADASIL: a diagnostic challenge

30. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults

31. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study

32. Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

33. The long‐term outcome of MOGAD: An observational national cohort study of 61 patients.

35. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.

36. Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies.

37. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.

41. Comparing Efficacy between Natalizumab and Fingolimod: Radiological Findings from BEST-MS Study (P1.352)

43. Efficacy and safety of alemtuzumab in 113 patients with active relapsing-remitting MS: one-year follow-up in France (P5.347)

46. CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

Catalog

Books, media, physical & digital resources